Study wrapper · #819
Semaglutide Injection in Indian Patients With Type 2 Diabetes Mellitus: A Randomised, Phase III, Active-Controlled Study.
Editor's note
A Phase III randomized non-inferiority trial directly about semaglutide — here comparing a synthetic semaglutide injection against reference-branded Ozempic in 314 Indian adults with type 2 diabetes inadequately controlled on metformin. Over 24 weeks, both arms lowered HbA1c substantially and comparably (Test -2.04%, Reference -1.95%), with the between-group difference (-0.09%) inside the pre-specified non-inferiority margin, and similar effects on glucose, weight, and the proportion reaching HbA1c below 7%. Adverse events were predominantly mild-to-moderate gastrointestinal in both arms, and no anti-drug or neutralising antibodies were detected — a relevant immunogenicity reassurance for a synthetic version. This is a legitimately high-tier design (randomized, active-controlled, multicentre) and directly peptide-specific. The main caveats are the open-label design and the 24-week horizon, which limits inference about durability and rarer harms. The finding is essentially a biosimilar-equivalence result rather than a novel efficacy claim, but it is solid and publishable.
Plain-language abstract
This was a randomized clinical trial — a high-quality study design — comparing two versions of the same drug, semaglutide, in 314 adults in India with type 2 diabetes that wasn't well controlled by metformin alone. One group received a newly made synthetic semaglutide injection; the other received the established branded product (Ozempic). Both were given as a weekly injection under the skin for 24 weeks, with the same gradual dose increase. By the end, both versions lowered long-term blood sugar (HbA1c) by very similar amounts — about 2 percentage points — and the tiny difference between them fell within the range the researchers had set to declare them equivalent. The two versions also produced similar improvements in blood glucose and body weight. Side effects were mostly mild-to-moderate stomach-and-gut issues in both groups, and no immune reactions against the drug were detected. The study suggests the synthetic version works about as well as the reference product over 24 weeks; because it was open-label and relatively short, longer studies would be needed to judge durability and rarer side effects.